88 related articles for article (PubMed ID: 15471908)
1. Combating atherosclerosis with LXR alpha and PPAR alpha agonists: is rational multitargeted polypharmacy the future of therapeutics in complex diseases?
Kino T; Chrousos GP
Mol Interv; 2004 Oct; 4(5):254-7. PubMed ID: 15471908
[No Abstract] [Full Text] [Related]
2. HDL-C as a new paradigm in atherosclerotic diseases.
Shilpha S; Bairy KL
Indian J Physiol Pharmacol; 2008; 52(4):319-26. PubMed ID: 19585750
[No Abstract] [Full Text] [Related]
3. Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis.
Hansen MK; Connolly TM
Curr Opin Investig Drugs; 2008 Mar; 9(3):247-55. PubMed ID: 18311660
[TBL] [Abstract][Full Text] [Related]
4. [Advances in the study of anti-atherosclerosis drugs].
Guo CB; Li S
Yao Xue Xue Bao; 2007 Mar; 42(3):231-5. PubMed ID: 17520819
[TBL] [Abstract][Full Text] [Related]
5. SAR studies: designing potent and selective LXR agonists.
Szewczyk JW; Huang S; Chin J; Tian J; Mitnaul L; Rosa RL; Peterson L; Sparrow CP; Adams AD
Bioorg Med Chem Lett; 2006 Jun; 16(11):3055-60. PubMed ID: 16529931
[TBL] [Abstract][Full Text] [Related]
6. The liver X receptor and atherosclerosis.
Scott J
N Engl J Med; 2007 Nov; 357(21):2195-7. PubMed ID: 18032771
[No Abstract] [Full Text] [Related]
7. Lesion macrophages are a key target for the antiatherogenic effects of LXR agonists.
Bradley MN; Tontonoz P
Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):10-1. PubMed ID: 15626767
[No Abstract] [Full Text] [Related]
8. Liver X receptor and farnesoid X receptor as therapeutic targets.
Rader DJ
Am J Cardiol; 2007 Dec; 100(11 A):n15-9. PubMed ID: 18047847
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and structure-activity relationship of podocarpic acid amides as liver X receptor agonists for potential treatment of atherosclerosis.
Liu W; Chen S; Dropinski J; Colwell L; Robins M; Szymonifka M; Hayes N; Sharma N; MacNaul K; Hernandez M; Burton C; Sparrow CP; Menke JG; Singh SB
Bioorg Med Chem Lett; 2005 Oct; 15(20):4574-8. PubMed ID: 16125384
[TBL] [Abstract][Full Text] [Related]
10. The liver X receptors.
Lala DS
Curr Opin Investig Drugs; 2005 Sep; 6(9):934-43. PubMed ID: 16187693
[TBL] [Abstract][Full Text] [Related]
11. Regulation of adiponectin receptor 1 in human hepatocytes by agonists of nuclear receptors.
Neumeier M; Weigert J; Schäffler A; Weiss T; Kirchner S; Laberer S; Schölmerich J; Buechler C
Biochem Biophys Res Commun; 2005 Sep; 334(3):924-9. PubMed ID: 16023994
[TBL] [Abstract][Full Text] [Related]
12. LXR agonists for the treatment of atherosclerosis.
Jaye M
Curr Opin Investig Drugs; 2003 Sep; 4(9):1053-8. PubMed ID: 14582448
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and SAR of potent LXR agonists containing an indole pharmacophore.
Washburn DG; Hoang TH; Campobasso N; Smallwood A; Parks DJ; Webb CL; Frank KA; Nord M; Duraiswami C; Evans C; Jaye M; Thompson SK
Bioorg Med Chem Lett; 2009 Feb; 19(4):1097-100. PubMed ID: 19167885
[TBL] [Abstract][Full Text] [Related]
14. Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis.
Demerjian M; Choi EH; Man MQ; Chang S; Elias PM; Feingold KR
Exp Dermatol; 2009 Jul; 18(7):643-9. PubMed ID: 19236478
[TBL] [Abstract][Full Text] [Related]
15. Liver x receptor agonists inhibit cytokine-induced osteopontin expression in macrophages through interference with activator protein-1 signaling pathways.
Ogawa D; Stone JF; Takata Y; Blaschke F; Chu VH; Towler DA; Law RE; Hsueh WA; Bruemmer D
Circ Res; 2005 Apr; 96(7):e59-67. PubMed ID: 15790955
[TBL] [Abstract][Full Text] [Related]
16. [Synthesis of (24S)-hydroxy- and (24S)-24,25-epoxycholesterol analogues, potential agonists of nuclear LXR receptors].
Khripach VA; Zhabinskiĭ VN; Antonchik AV; Antonchik AP
Bioorg Khim; 2006; 32(6):651-9. PubMed ID: 17180916
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic opportunities for liver X receptor modulators.
Collins JL
Curr Opin Drug Discov Devel; 2004 Sep; 7(5):692-702. PubMed ID: 15503871
[TBL] [Abstract][Full Text] [Related]
18. Steroidal and triterpenoidal fungal metabolites as ligands of liver X receptors.
Ondeyka JG; Jayasuriya H; Herath KB; Guan Z; Schulman M; Collado J; Dombrowski AW; Kwon SS; McCallum C; Sharma N; MacNaul K; Hayes N; Menke JG; Singh SB
J Antibiot (Tokyo); 2005 Sep; 58(9):559-65. PubMed ID: 16320760
[TBL] [Abstract][Full Text] [Related]
19. Modulation of liver X receptor signaling as novel therapy for prostate cancer.
Chuu CP; Kokontis JM; Hiipakka RA; Liao S
J Biomed Sci; 2007 Sep; 14(5):543-53. PubMed ID: 17372849
[TBL] [Abstract][Full Text] [Related]
20. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men.
Rigamonti E; Chinetti-Gbaguidi G; Staels B
Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1050-9. PubMed ID: 18323516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
